- Home
- Products
Portrazza (Necitumumab)
Portrazza (Necitumumab)
- Medicine Name: Portrazza
- Generic Name: Necitumumab
- Dosage Form & Strength: Injection – 800 mg/50 mL (16 mg/mL) solution in a single-dose vial
- Manufactured By: Eli Lilly and Company
Portrazza (Necitumumab) is an EGFR (epidermal growth factor receptor) antagonist used in combination with cisplatin and gemcitabine for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).
Note: Portrazza is not indicated for the treatment of non-squamous NSCLC.
Recommended Dosage:
- 800 mg IV infusion over 60 minutes on Days 1 and 8 of each 3-week cycle.
- Administer prior to gemcitabine and cisplatin.
- Continue until disease progression or unacceptable toxicity.
Pre-medication:
- If prior Grade 1/2 infusion reactions occur: Pre-medicate with diphenhydramine.
- For repeated Grade 1/2 IRRs: Use diphenhydramine, acetaminophen, and dexamethasone prior to all future infusions.
Electrolyte Imbalances: Monitor serum magnesium, calcium, and potassium before each infusion and for at least 8 weeks after the final dose.
Hypomagnesemia: May lead to complications. Monitor and correct imbalances as needed.
Thromboembolic Events (VTE/ATE): Discontinue treatment in patients experiencing severe or life-threatening events.
Dermatologic Toxicity: Includes rash, dry skin, acneiform dermatitis, pruritus, and skin fissures. Discontinue for Grade 4 or severe Grade 3 reactions.
Infusion Reactions: Monitor for signs during and after infusion. Discontinue for serious or life-threatening IRRs.
Pregnancy Warning: Portrazza may harm an unborn child. Women should use contraception during treatment and for 3 months after the last dose.
Required Documents for Import:
- Valid prescription from a qualified doctor
- Patient’s diagnostic reports
- Government-issued ID proof
Order Confirmation:
- Confirmed only after receipt of prescription and applicable import permit
Availability in India: Portrazza is accessible in India via Global Rare Meds under the Named Patient Program. Available in cities including Mumbai, Delhi, Kolkata, Chennai, Hyderabad, Bangalore, Ahmedabad, Pune, Chandigarh, and more.
We ensure sourcing from authorized and reliable global suppliers.
Contact for Pricing & Orders:
- Phone/WhatsApp: +91-99675 15602
- Email: info@globalraremeds.com
Global Rare Meds sources Portrazza (Necitumumab) from certified suppliers across the USA, Europe, and other regulated markets. All prescriptions are validated by registered pharmacists and dispatched from our fulfillment center in Ambernath, Thane District, India.
Delivery is available to patients across India and eligible international locations through legal and compliant supply chains.
What is the Generic Name of Portrazza®?
Necitumumab
Who manufactures Portrazza®?
Eli Lilly and Company
Is Portrazza® FDA approved?
Yes. Approval date: November 24, 2015
What is the form and dosage of Portrazza®?
Injection: 800 mg/50 mL (16 mg/mL) for IV use
Where can I buy Portrazza® in India?
Contact Global Rare Meds for safe and verified access with a valid prescription.
Common side effects of Portrazza®?
Rash and hypomagnesemia are the most frequently reported.
What are the storage conditions?
Refrigerate at 2–8°C. Protect from light. Do not shake or freeze.
How much does Portrazza® cost in India?
Prices may vary. Contact Global Rare Meds at +91-99675 15602 or info@globalraremeds.com for current pricing.
Is it safe to buy Portrazza® online in India?
Yes, through Global Rare Meds using secure, legal import pathways for unregistered or unavailable medicines.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
